With positive interim results from a global Phase II study in hand, the management at Hope Medicine (HopeMed), a Chinese biotech specialized in women’s health, is entertaining hopes of a first-line treatment for endometriosis-associated pain.
The firm’s lead asset is HMI-115, a once-biweekly, subcutaneously administered antibody that blocks the prolactin receptor.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?